(Q43000568)

12 November 2017

title

Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders (English)

1 reference

12 November 2017

0 references

1 reference

2

1 reference

12 November 2017

7

Marianthi Markatou

1 reference

12 November 2017

8

Alan S Perelson

1 reference

12 November 2017

1

Andrew H Talal

1 reference

12 November 2017

3

Kimberly A Powers

1 reference

12 November 2017

Michael Grace

4

1 reference

12 November 2017

Constance Cullen

series ordinal

5

1 reference

12 November 2017

Musaddeq Hussain

series ordinal

6

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

12 November 2017

1 reference

12 November 2017

volume

43

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

943-953

1 reference

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

12 November 2017

cites work

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

7 January 2021

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

7 January 2021

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

7 January 2021

Dynamics of alanine aminotransferase during hepatitis C virus treatment

1 reference

7 January 2021

Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b

1 reference

7 January 2021

Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study

1 reference

7 January 2021

Hepatitis C viral kinetic models

1 reference

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

7 January 2021

Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1

1 reference

7 January 2021

Pharmacokinetics of peginterferons

1 reference

7 January 2021

Classification of chronic viral hepatitis: a need for reassessment

1 reference

7 January 2021

Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions

1 reference

7 January 2021

A proposed system for the nomenclature of hepatitis C viral genotypes

1 reference

7 January 2021

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

1 reference

7 January 2021

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

7 January 2021

Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C.

1 reference

7 January 2021

Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV.

1 reference

7 January 2021

First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline

1 reference

7 January 2021

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection

1 reference

7 January 2021

Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients

1 reference

7 January 2021

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

1 reference

7 January 2021

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

1 reference

7 January 2021

Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase

1 reference

7 January 2021

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

1 reference

7 January 2021

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

7 January 2021

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

1 reference

7 January 2021

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

7 January 2021

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

1 reference

7 January 2021

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21136

1 reference

release_gqpyaccusbeabcgjug72ugieai

12 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gqpyaccusbeabcgjug72ugieai

24 November 2022

mapped directly with Wikidata item

1 reference